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Abstract The sphingolipid metabolite sphingosine-1-phosphate
(S1P) is a serum-borne lipid that regulates many vital cellular
processes. S1P is the ligand of a family of ¢ve speci¢c G pro-
tein-coupled receptors that are di¡erentially expressed in di¡er-
ent tissues and regulate diverse cellular actions. Much less is
known of the intracellular actions of S1P. It has been suggested
that S1P may also function as an intracellular second messenger
to regulate calcium mobilization, cell growth and suppression of
apoptosis in response to a variety of extracellular stimuli. Dis-
secting the dual actions and identi¢cation of intracellular targets
of S1P has been challenging, but there is ample evidence to
suggest that the balance between S1P and ceramide and/or
sphingosine levels in cells is an important determinant of cell
fate.
* 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid
metabolite formed by the phosphorylation of sphingosine by
sphingosine kinase. Like many other sphingolipids, S1P was
long thought to be mainly a degradative metabolite of sphin-
golipids formed during turnover of eukaryotic cell mem-
branes. However, since our discovery over 10 years ago that
S1P plays an important role in cell growth regulation [1], it
has been implicated in many and diverse biological processes,
such as cell growth, di¡erentiation, cell survival, angiogenesis,
cell migration (reviewed in [2^5]), and more recently, in the
regulation of immune function by in£uencing mast and T cell
functions and lymphocyte tra⁄cking [6^8]. With the discovery
that S1P can bind to speci¢c cell surface G protein-coupled
receptors, the concept emerged that S1P can function as an
extracellular ¢rst messenger and perhaps as an intracellular
second messenger, and these dual functions as well as ¢ve
speci¢c receptors may explain the diverse biological processes
reported to be regulated by this lipid mediator. This review is
focused on the inside^outside functions of S1P.
2. Extracellular actions of S1P: ¢rst messenger functions
In the last few years, interest in the role of S1P has accel-
erated with the ¢nding that S1P is the natural ligand of the
orphan G protein-coupled receptor EDG-1 (now called S1P1)
[9,10], and with the subsequent identi¢cation of four other
family members with high speci¢city for S1P and dihydro-
S1P: S1P2, S1P3, S1P4 and S1P5 (reviewed in [3]). These
G protein-coupled receptors are di¡erentially expressed in dif-
ferent tissues, and couple to a variety of G proteins that
regulate various signal transduction pathways. As a result,
S1P can potentially stimulate diverse signal transduction path-
ways in di¡erent cell types as well as within the same cell,
resulting in the possibility of diverse biological outcomes, de-
pending on the cell type, G proteins that are present, and the
pattern of S1P receptor (S1PR) expression (Fig. 1).
One of the more widely studied functions of extracellular
S1P is the regulation of cell migration and its role in angio-
genesis. S1P stimulates directed migration of endothelial cells
[11] and vascular smooth muscle cells [12,13], critical events in
the formation and extension of new blood vessels, as well as
promoting capillary-like tube formation by bovine aortic en-
dothelial cells [11]. These events appear to be mediated pri-
marily by the binding of S1P to S1P1 and the subsequent
activation of a pertussis toxin-sensitive Gi protein. The role
of S1P and S1P1 in angiogenesis has been further substanti-
ated by disruption of the s1p1 gene in mice. These mice die at
embryonic day 13.5 from hemorrhage due to incomplete mat-
uration of the vascular system [14]. Moreover, ¢broblasts iso-
lated from these embryos fail to migrate in response to plate-
let-derived growth factor (PDGF) or S1P and fail to activate
the small GTPase Rac, known to be involved in cell migra-
tion. Collectively, these data reveal an important role for
extracellular S1P and S1P1 in vascular maturation. In addi-
tion to endothelial and smooth muscle cells, S1P also acts as a
chemoattractant for hematopoietic precursor cells [15] and
immature dendritic cells [16], raising the possibility that S1P
may control the recruitment of in£ammatory cells to sites of
in£ammation and help modulate the immune response. In-
deed, recent studies have shown that lymphocyte tra⁄cking
is altered by S1P and by a sphingosine kinase-produced phos-
phorylated metabolite of the immunosuppressive agent
FTY720 [7,8]. Phosphorylated FTY720 was a high a⁄nity
agonist of at least four of the ¢ve S1P receptors and induced
emptying of lymphoid sinuses and inhibition of egress into
lymph. These observations have important clinical implica-
tions for sphingolipids in immunosuppression [7,8].
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Like S1P1, S1P3 appears to be involved in stimulation of
cell migration mediated by S1P and regulation of cytoskeletal
rearrangements and membrane ru¥ing associated with cell
motility [17^19]. In addition to its intracellular anti-apoptotic
role, binding of S1P to S1P3 has also been shown to enhance
survival by suppression of Bax expression and activation of
endothelial nitric oxide synthase, phosphatidylinositol 3-ki-
nase and Akt [19^21]. Contrary to the stimulatory e¡ects of
S1P1 and S1P3, activation of S1P2 inhibits cell migration [17].
That S1P can both stimulate and inhibit cell migration at ¢rst
appears contradictory, but the net e¡ect of S1P on cell migra-
tion may depend on the relative levels of receptor expression,
receptor turnover, and S1P concentrations. Indeed, at low
concentrations, S1P induced smooth muscle cell migration
but at higher concentrations it was inhibitory [12]. Another
e¡ect of S1P is the induction of neurite retraction and neuro-
nal cell rounding, mediated through S1P3 [22]. Much less is
known about the function of S1P5. It is, however, highly ex-
pressed in oligodendrocytes and astrocytes [23] and S1P in-
hibits extracellular signal-regulated kinase (ERK) activation
and proliferation in cells overexpressing S1P5 [24]. It is there-
fore possible that S1P/S1P5 signaling may play an important
role in nervous system development.
Activation of a number of signaling pathways attributed to
extracellular S1P may account for some of the observed bio-
logical e¡ects. The activation of the small GTPases Rac and
Rho [17,25] has been linked to cytoskeletal rearrangements
and motility. Other relevant signaling pathways include acti-
vation of the ERK and p38 mitogen-activated protein kinases
[26], intracellular calcium mobilization, and activation of
phospholipase D and Akt.
The existence of multiple signaling pathways induced by
S1P and the expression of multiple S1PRs might suggest
some redundancy in S1P functions. The lethality of S1P1-
null mice indicates that S1P1 has unique functions not shared
by other S1PRs. Moreover, it was recently shown by the use
of single and double S1P2/S1P3-null mice that S1P2 and S1P3
share some functions, such as activation of Rho, but that
S1P3 alone may play a major role in calcium mobilization
[27]. Interestingly, although surviving S1P2/S1P3-null mice ap-
peared to develop normally, litter sizes were greatly reduced
and there was increased perinatal death, suggesting redundan-
cies in S1P2 and S1P3 functions vis-a'-vis perinatal develop-
ment.
Recently, we showed that in C6 astroglioma cells, intracel-
lular S1P plays a role in the regulation of tumor necrosis
factor-K (TNF-K)-induced activation of GTP cyclohydrolase
expression and synthesis of tetrahydrobiopterin, a co-factor
required for nitric oxide synthase activity [28]. Surprisingly,
we found that, although C6 cells can secrete S1P, which is
enhanced by TNF-K, treatment of C6 cells with exogenous
S1P or dihydro-S1P had no e¡ect on tetrahydrobiopterin bio-
synthesis. However, both S1P and dihydro-S1P markedly
stimulated ERK1/2 in C6 cells, which express cell surface
S1P receptors. Interestingly, although this ERK activation
was blocked by PD98059, which also reduced cellular prolif-
eration induced by enforced expression of sphingosine kinase,
PD98059 had no e¡ect on GTP cyclohydrolase activity [28].
Collectively, these results suggest that only intracellularly gen-
erated S1P plays a role in regulation of GTP cyclohydrolase
activity and tetrahydrobiopterin levels. This is one of the few
studies that clearly show a distinct di¡erence between intra-
cellular and extracellular actions of S1P.
3. S1P is a second messenger
Studies from our lab and many others have implicated S1P
as a second messenger in cellular proliferation, cell survival
and suppression of apoptosis (Fig. 1, reviewed in [29]). Fur-
thermore, a variety of growth factors and cytokines, including
PDGF, epidermal growth factor, TNF-K, and nerve growth
factor, which are well known inducers of cellular proliferation
and/or di¡erentiation, also activate sphingosine kinase, the
enzyme that forms S1P from sphingosine, and thereby increas-
ing cellular S1P levels [30^32]. An early clue that S1P may
play a role as a second messenger mobilizing calcium from
internal sources independently of inositol trisphosphate arose
with the ¢nding that sphingosine derivatives generated inside
cells stimulated the release of calcium [33].
In many of the initial studies, S1P was added exogenously
to elevate cellular levels, and although S1P can be rapidly
taken up by cells, this approach led to some confusion be-
cause it was di⁄cult to determine the site of action of S1P.
With the cloning of sphingosine kinase and the development
of speci¢c molecular tools to increase intracellular levels of
S1P, some evidence has surfaced to suggest that intracellular
S1P plays a key role in cell growth and survival [34]. More-
over, speci¢c inhibitors of sphingosine kinase also inhibit cell
proliferation and survival induced by various stimuli as well
as sphingosine kinase overexpression (reviewed in [35]).
The intracellular targets of S1P remain much more elusive.
Although no direct targets have yet been conclusively identi-
¢ed, there are some provocative clues for future searches.
Microinjection of S1P into ¢broblasts increases DNA synthe-
sis [9] and calcium mobilization from internal stores [36].
PDGF induces translocation of sphingosine kinase to the nu-
clear envelope with a concomitant increase in nucleus-associ-
ated sphingosine kinase activity [37]. This implies that S1P
may have a role in the nucleus, and it was suggested that it
may be involved in cell cycle progression, although no direct
evidence for this has yet appeared.
S1P has also been shown to activate ERK [38] and inhibit
c-Jun N-terminal kinase (JNK) activation [39], which is sig-
ni¢cant since the balance of ERK and JNK activation has
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been implicated in the control of apoptosis [40]. Moreover,
ceramide, another sphingolipid metabolite that induces apo-
ptosis in many cell types (reviewed in [41]), opposes the e¡ects
of S1P on these pathways [39]. This, as well as the opposing
e¡ects of S1P and ceramide on the induction of apoptosis, has
led to the model in which the dynamic balance of S1P and
ceramide determines the fate of the cell. More recently, ele-
vated sphingosine levels in mast cells have been shown to
inhibit allergic activation and production of leukotrienes,
whereas elevated S1P levels resulted in activation of mast cells
and increased leukotriene production [42], supporting the no-
tion that the balance of intracellular sphingolipid metabolites
controls many biological responses. As would be expected for
an intracellular signaling molecule, the levels of S1P in cells
are low and tightly regulated by the balance between sphin-
gosine kinase-dependent synthesis and degradation by an en-
doplasmic pyridoxal phosphate requiring lyase and by phos-
phohydrolases. Recently, a speci¢c S1P phosphohydrolase
was cloned and characterized [43]. Overexpression of this
S1P-degrading enzyme decreased cellular S1P levels, increased
sphingosine and ceramide, and promoted apoptosis, in further
support of the model in which the dynamic balance of S1P
and ceramide determines the fate of the cell [43].
4. Does S1P signal inside-to-outside, outside-to-inside, or both?
As discussed above, it is now well accepted that extracellu-
lar S1P is an important mediator of many physiological pro-
cesses. The early studies demonstrating that PDGF activated
sphingosine kinase, thereby increasing intracellular S1P levels,
implicated a role for intracellular S1P in cell survival, prolif-
eration and the inhibition of apoptosis [30,39]. However, the
¢ndings that extracellular S1P can inhibit apoptosis [20,21],
stimulate proliferation of mesangial cells [44], and inhibit pro-
liferation of hepatic myo¢broblasts [45] have raised the pos-
sibility that S1P may have simultaneous dual functions in
many of these biological processes (Fig. 1). Our recent discov-
ery that PDGF-directed cell motility requires cross-talk from
the PDGF receptor to S1P1 via activation of sphingosine ki-
nase and formation of S1P led us to put forward the idea that
intracellular S1P can either be secreted or di¡use across the
plasma membrane and activate cell surface S1PRs in an auto-
crine or paracrine manner [13]. PDGF also stimulates and
induces translocation of sphingosine kinase to the leading
edge of migrating cells [46], resulting in the formation of a
steep, extracellular S1P gradient at the leading edge of a mi-
grating cell, thereby directing cell movement. Together these
data suggest an inside-to-outside signaling paradigm whereby
an agonist induces intracellular production of S1P, which then
stimulates its receptor present on the same cell. This mode of
action makes the elucidation of intracellular vs. extracellular
S1P signaling pathways even more challenging. Some other
complicating factors are that sphingosine kinase can also be
secreted by endothelial cells [47], suggesting that S1P gener-
ated directly in the extracellular space may contribute to cell
migration and angiogenesis, and extracellular S1P may even
stimulate its own intracellular production [48].
Transport of S1P in and out, as well as within cells has
received little attention. The ¢nding that the cystic ¢brosis
transmembrane regulator (CFTR), a member of the ABC
family of transmembrane transporters, is also a S1P trans-
porter that can regulate the uptake of S1P may provide a
mechanism by which S1P can cross the plasma membrane in
a regulated manner [49]. Although it is not known whether
CFTR can also mediate secretion of S1P, this transporter
could provide a mechanism by which cells modulate extracel-
lular S1P signaling through its internalization.
In conclusion, a better understanding of S1P signaling path-
ways, whether intra- or extracellular, may prove to be useful
in identifying targets for the development of therapeutics for a
number of disease states. There is much interest in the devel-
opment of S1P antagonists or sphingosine kinase inhibitors
for the treatment of cancer since S1P plays such an important
role regulating cell proliferation, survival, migration and vas-
cularization, all critical processes in cancer cell biology. Of
note, S1P is a lipid component of both high density and
low density lipoproteins and may play a role in atherogenesis
and heart disease, although it is as yet unclear whether S1P is
a pro- or anti-atherogenic mediator (reviewed in [50]). Mod-
ulation of S1P signaling may also prove to be useful in thera-
pies for asthma and allergy. A challenging task still at hand is
the conclusive demonstration of intracellular actions indepen-
dent of known S1PRs and identi¢cation of intracellular tar-
gets of S1P.
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